Skip to main content
Premium Trial:

Request an Annual Quote

Alere Q2 Revenues Drop 9 Percent as Cardiometabolic, Infectious Disease Sales Decline

NEW YORK (GenomeWeb) – Alere on Thursday reported that its second quarter revenues fell 9 percent year over year, driven primarily by sinking sales in its cardiometabolic disease and infectious disease test segments.

For the three months ended June 30, the firm reported revenues of $557.7 million compared to restated revenues of $610.3 million in Q2 2016. The firm said that its financial results for Q2 reflect a $6 million negative impact of foreign currency exchange.

Sales for its cardiometabolic disease tests declined 16 percent year over year to $140 million from $167 million, while infectious disease test sales dropped 12 percent to $167 million from $189 million, toxicology test revenues rose 1 percent to $160 million from $158 million, and consumer diagnostics sales were down 17 percent to $17 million from $20 million. Sales declined 4 percent for its "other" tests to $35 million from $36 million, and were flat for its "other non-reportable" segment at $37 million and for license and royalty revenues at $3 million.

Alere reported a net loss of $92.7 million, or $1.13 per share, compared to a net loss of $32.8 million, or $.44 per share, for Q2 2016.

Alere is in the process of being acquired by Abbott for $5.3 billion. The transaction is expected to close by the end of the third quarter.

Alere said its R&D spending for the quarter rose 4 percent to $29.4 million from $28.4 million, while its SG&A expenses jumped 5 percent to $252.2 million from $239.3 million.

The firm finished the quarter with $491.7 million in cash and cash equivalents, $52.5 million in restricted cash, and $150,000 in marketable securities.

Alere's financial results for Q2 2016 reflected restatements of revenues stemming from incorrectly recorded revenue transactions by its Standard Diagnostics subsidiary in South Korea.

On Friday, Alere's shares were down less than 1 percent at $49.38 in morning trading on the Nasdaq.


The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.